With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B

With a new $110 million series B led by Medicxi, Seattle-based Curevo is moving a potential competitor to blockbuster shingles vaccine Shingrix toward pivotal testing, touting a tolerability advantage that could position it as a preferred option.

The investor syndicate believes Curevo Inc.’s amezosvatein (CRV-101), which uses a purified form of a TLR4 agonist as its adjuvant, could take market share from Shingrix. The incumbent herpes zoster vaccine delivered £3.4 billion ($4.4 billion) in 2024 sales to GSK plc (LSE:GSK; NYSE:GSK)...